Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2002
01/17/2002US20020006953 Modification of cholesterol concentrations with citus phytochemicals
01/17/2002US20020006952 Kinase inhibitors; anticancer agents
01/17/2002US20020006951 Solid-state form of celecoxib having enhanced bioavailability
01/17/2002US20020006950 Peroxidsome proliferator activated receptors
01/17/2002US20020006949 Medicament
01/17/2002US20020006947 Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof
01/17/2002US20020006946 Obesity, antidiabetic agents, cardiovascular disorders
01/17/2002US20020006945 Immunology diseases
01/17/2002US20020006943 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
01/17/2002US20020006942 Antiinflammatory agents
01/17/2002US20020006941 p53 inhibitors and therapeutic use of the same
01/17/2002US20020006939 Insulin sensitizer
01/17/2002US20020006937 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
01/17/2002US20020006936 Anticancer agents; restenosis
01/17/2002US20020006934 Phenyl-substituted imidazopyridines
01/17/2002US20020006933 Method for treating sexual dysfunction with apomorphine at specified plasma concentration levels
01/17/2002US20020006932 Central nervous system disorders; heeadaches, antiinflammatory agents
01/17/2002US20020006931 Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
01/17/2002US20020006930 Method for stimulating liver regeneration
01/17/2002US20020006929 Antiarrhythmia agent, antiproliferative agent
01/17/2002US20020006928 Phenyl-substituted indoles and indazoles
01/17/2002US20020006926 Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
01/17/2002US20020006923 Thrombin inhibitors
01/17/2002US20020006922 Metalloprotease inhibitors
01/17/2002US20020006921 Dopaminergic agent
01/17/2002US20020006919 Drugs, solid form
01/17/2002US20020006918 Prostate cancer
01/17/2002US20020006917 Method of locking 1alpha-OH of vitamin D compounds in axial orientation
01/17/2002US20020006916 Promoters of neural regeneration
01/17/2002US20020006915 Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
01/17/2002US20020006913 Maintenance of Dna; reduce damage
01/17/2002US20020006911 Administering mixture of jasmone, antioxidant and carnitine
01/17/2002US20020006910 Means for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome and a method for allaying drunkenness, preventing and removing alcohol intoxication and hangover syndrome by using this means
01/17/2002US20020006909 Liver and respiratory system disorders
01/17/2002US20020006908 Anticonvulsant derivatives useful in treating schizophrenia
01/17/2002US20020006899 Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
01/17/2002US20020006898 Trimethyl lock based tetrapartate prodrugs
01/17/2002US20020006895 Method of treatment of cardiovascular injuries
01/17/2002US20020006640 Uteroglobin-like polynucleotides, polypeptides, and antibodies
01/17/2002US20020006630 Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
01/17/2002US20020006449 By applying Capsaicin topically, where disappearance, atrophication and de-coloration of treated area is achieved
01/17/2002US20020006447 Anti-chlamydia agent
01/17/2002US20020006445 Composition and method for treating the effects of diseases and maladies
01/17/2002US20020006442 Injectable aqueous dispersions of propofol
01/17/2002US20020006441 Pharmaceutical composition containing diphosphonic acid or salt thereof
01/17/2002US20020006435 Local, topical transdermal anesthetic and vasodilator formulation of a topical anesthetic, topical vasodilator, and carrier; use prior to inserting an intravenous line into a patient
01/17/2002US20020006433 Chewable tablet comprising amoxycillin trihydrate in which the chewable base comprises mannitol which is at least twenty-five percent by weight of the tablet; treating bacterial infection in a pediatric patient
01/17/2002US20020006430 Angiotensin converting enzyme (ACE) inhibitor; controlled release diltiazem in the core in combination with a rapid release ACE inhibitor, or diuretic, in an external coat; pharmacokinetics; easier to swallow; treating hypertension
01/17/2002US20020006421 Long-acting, chemical-resistant skin emollients, moisturizers, and strengtheners
01/17/2002US20020006420 Use of a 2-amino-alkane polyol as agent for treating skin ageing signs
01/17/2002US20020006418 Composition to enhance permeation of topical skin agents
01/17/2002US20020006407 Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
01/17/2002US20020006399 Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
01/17/2002US20020006393 Compounds for the photodecontamination of pathogens in blood
01/17/2002US20020006391 Genetic engineering
01/17/2002US20020006389 Containing cationic silicone polymer
01/17/2002US20020006384 Using fluorohydrocarbons as propellant
01/17/2002US20020006383 Promoter of biosynthesis of skin cells
01/17/2002US20020006381 Method for finding nucleotide synthesis inhibitors having fewer side effects
01/17/2002US20020006380 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them
01/17/2002US20020005206 Antiproliferative drug and delivery device
01/17/2002US20020005028 Methods of producing a terminally sterilized topical patch preparation
01/17/2002DE10033337A1 Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel Biphenylcarbonsäureamide, their preparation and their use as medicaments
01/17/2002DE10032880A1 Anthelmintika zur Verhinderung von parasitären Infektionen bei Mensch und Tier IV Anthelmintics for the prevention of parasitic infections in humans and animals IV
01/17/2002DE10032879A1 Anthelmintika zur Verhinderung von parasitären Infektionen bei Mensch und Tier II Anthelmintics for the prevention of parasitic infections in humans and animals II
01/17/2002DE10032878A1 Anthelmintika zur Verhinderung von parasitären Infektionen bei Mensch und Tier Anthelmintics for the prevention of parasitic infections in humans and animals
01/17/2002DE10032242A1 Medicinal use of galiella lactone as specific interleukin-6 signal induction inhibitor e.g. in treatment of fibrotic, cerebrovascular or neurodegenerative disease, pain, inflammation or tumors
01/17/2002DE10032132A1 Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung A dermal therapeutic system containing NSAIDs with selective COX-2 inhibition
01/17/2002DE10031457A1 Verwendung von Flavon-/Flavanon-Derivaten zur systemischen Behandlung von Prophylaxe von UV-induzierten Dermatosen und unerwünschten Langzeitfolgen von UV-Bestrahlungen Use of flavone / flavanone derivatives for the systemic treatment of prevention of UV-induced dermatoses and adverse long-term effects of UV radiation
01/17/2002DE10005302A1 Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives
01/17/2002CA2416199A1 Adenosine compound and pharmaceutical composition containing the same
01/17/2002CA2416050A1 Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
01/17/2002CA2415760A1 Methods of producing weight loss and treatment of obesity
01/17/2002CA2415695A1 Compositions and methods for treatment of anal fissure
01/17/2002CA2415630A1 Tablet obtained by direct compression comprising 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid as active ingredient
01/17/2002CA2415624A1 Compositions and methods for treating cardiovascular disorders
01/17/2002CA2415569A1 Fungal cell wall synthesis gene
01/17/2002CA2415547A1 Process for preparing benzoxazin-4-one polymer conjugates
01/17/2002CA2415498A1 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
01/17/2002CA2415492A1 Pyrazole derivatives
01/17/2002CA2415483A1 Antisense compositions targeted to .beta.1 adrenoceptor-specific mrna and methods of use
01/17/2002CA2415422A1 Chromosome 3p21.3 genes are tumor suppressors
01/17/2002CA2415172A1 13-substituted methacycline compounds
01/17/2002CA2415100A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
01/17/2002CA2415093A1 Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
01/17/2002CA2415092A1 Novel aerosol formulation containing a polar fluorinated molecule
01/17/2002CA2415086A1 7,8 and 9-substituted tetracycline compounds
01/17/2002CA2415082A1 Method for formulating healthcare products with enhanced stability
01/17/2002CA2415081A1 Drug delivery system for poorly water soluble drugs
01/17/2002CA2415080A1 Improved thyroid hormone formulations
01/17/2002CA2415058A1 Pharmaceutical compositions of estrogenic agents
01/17/2002CA2415052A1 Combinations of bisphosphonates, estrogenic agents and optionally estrogens
01/17/2002CA2414938A1 Combinations of ssri and estrogenic agents
01/17/2002CA2414480A1 Fatty acid analogues for the treatment of cancer
01/17/2002CA2414455A1 Pharmaceutical composition and method for the treatment of retroviral infections
01/17/2002CA2414198A1 Melanin concentrating hormone receptor ligands
01/17/2002CA2414188A1 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
01/17/2002CA2414112A1 Treatment of male sexual dysfunction
01/17/2002CA2414111A1 Use of substituted indole compounds for increasing nitric oxide synthase activity
01/17/2002CA2414060A1 Combinations of statins, estrogenic agents and optionally estrogens